Zimbabwe has turned down a significant American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years because of the United States' demand for sensitive data.
The decision came to light following a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa felt the agreement was "unbalanced".
An official spokesperson has since explained that the US was demanding access to genetic material for scientific study and commercial purposes but was not willing to guarantee the benefits from future vaccines.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated over $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued talks to secure a deal suitable to all parties so the country's vital HIV programme can continue.
Broader Implications
Zimbabwe's decision follows a comparable case in Kenya, where a high court halted a similar deal with the US following legal challenges were filed about the safety of Kenyans' health data.
After resuming office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump claimed its spending was "wasteful" and his administration was seeking government-to-government deals to boost openness and responsibility.
Based on statements, 16 African countries have so far signed similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment through US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any equivalent guarantee of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our nation would provide the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our people should a new health crisis emerge."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were upending systems already established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.
"This framework is designed to guarantee that when a nation contributes its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to create them."
These objections over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage further discussions with our US partners on how future collaboration could be arranged in a way that respects the sovereignty and interests of each country."
Health Experts Reaction
A leading public health body said it understood the official position, but suggested that talks need to persist since much of the country's HIV programmes were funded by foreign aid.
"Where technical issues arise, such as those involving information security or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
The halted deal emphasises the ongoing challenges between receiving vital foreign assistance and protecting national sovereignty in an ever more data-driven world.